Panel Discussion: The Future of Oligonucleotide Therapeutics: Where Will the Field Be in 5 Years?
Time: 3:30 pm
day: Day 2
Details:
- How will advances in conjugation strategies, nanoparticle formulations, and tissue-specific targeting improve oligonucleotide biodistribution and efficacy?
- Beyond ALS, Huntington’s Disease & Alzheimer’s. What new indications, such as neurogenetic, epilepsies, neurodevelopmental and neuropsychiatric, are emerging for oligonucleotide-based therapies?
- What hurdles remain in scaling oligonucleotide production, and how will evolving regulatory frameworks shape the clinical and commercial landscape?
- How will AI and ML accelerate oligonucleotide drug discovery, from sequence optimization to in silico toxicity prediction?
